FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy 

FibroGen announced topline data from their Phase 3 trials of their novel antifibrotic agent, pamrevulmab, a connective tissue growth factor antibody for the treatment for ambulatory individuals with Duchenne. While pamrevlumab was generally safe and well tolerated, the study unfortunately did not meet the primary endpoint.  Pamrevlumab also failed to meet its primary endpoint in non-ambulatory individuals earlier this year. 

Decoding Gene Therapy for Duchenne

While there is currently no cure for Duchenne muscular dystrophy, gene therapy has the potential to target the underlying genetic cause of many mono genetic diseases and could potentially benefit […]